|Awarded On||February 19, 2020|
|Title||Development of a Novel Approach to Cancer Immunotherapy by Targeting Extracellular Tumor- derived HSP70 to Dendritic Cells|
|Program||Product Development Research|
|Award Mechanism||Seed Awards for Product Development Research|
|Principal Investigator/Program Director||Jeno Gyuris|
|Cancer Sites||Breast, Myeloma, Pancreas|
Immunotherapy is making a meaningful impact on clinical outcomes but only a small fraction of patients achieve durable benefits because cancer can become invisible to the body’s immune system. Our team is developing a novel antibody to Heat shock protein (HSP)-70 created at MD Anderson that works by increasing the ability of dendritic cells, which are key to starting immune reactions, to better recognize the presence of cancer cells. As a result, T-cells become activated to kill cancer cells, and our studies show that this antibody, known as ASY-77A, is active against models of solid tumors such as breast, colon cancer, and melanoma, and against blood-related cancers like multiple myeloma. W...